With the surge in COVID-19 cases and the emergence of multiple subvariants in India, it is crucial to review your health insurance coverage and ensure it is sufficient. Moreover, there is concern about the JN.1 sub-variant, with its initial case reported in Kerala. JN.1 is derived from the "pirola" variant BA 2.86, itself an Omicron subvariant. Unlike BA 2.86, JN.1 features an additional mutation in the receptor binding domain (L455S). JN.1 exhibits significant resistance across receptor binding domain classes one, two, and three, displaying higher immune evasion compared to BA 2.86 and other resistant strains. The World Health Organization (WHO) has designated JN.1 as a variant of interest. Dr. Rajeev Jayadevan from the IMA COVID Task Force highlighted on Thursday that this new strain could pose challenges, particularly for elderly individuals and those with multiple co-morbidities.